Therapeutics News and Research

RSS

Stem cell transplantation may offer viable treatment for Alzheimer's disease patients

Alzheimer's disease (AD), affecting millions worldwide, is the leading cause of dementia. The prevalence of AD is rapidly increasing, and will possibly affect over 100 million people by 2050, yet there are no effective therapies for the disease.

31 Oct 2015

Q BioMed signs definitive license agreement with Mannin Research

Q BioMed Inc., a biotechnology acceleration company is pleased to announce it has signed a definitive license, with the option to acquire, the platform technology assets of Mannin Research Inc.

30 Oct 2015

Specialized type of immunotherapy can boost survival from pancreatic cancer

A new study in mice by researchers at Fred Hutchinson Cancer Research Center has found that a specialized type of immunotherapy — even when used without chemotherapy or radiation — can boost survival from pancreatic cancer, a nearly almost-lethal disease, by more than 75 percent. The findings are so promising, human clinical trials are planned within the next year.

30 Oct 2015

New online tool may allow researchers explore formation of hair follicles

A new online database will empower researchers exploring how hair follicles and the surrounding skin develop, according to an article published recently in the journal Developmental Cell. The work is central to understanding the interactions between stem cells and their environment - or "niche cells" - during fetal development, and will specifically facilitate future attempts to make skin grafts with functional hair follicles or to regenerate lost hair in patients.

30 Oct 2015

Isis Pharmaceuticals begins ISIS-FXI Rx Phase 2 study in patients with ESRD on hemodialysis

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 study evaluating ISIS-FXIRx in patients with end-stage renal disease (ESRD) on hemodialysis. In May 2015, Isis entered into an exclusive license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx for the prevention of clotting disorders.

30 Oct 2015

Halozyme Therapeutics announces initiation of rivipansel Phase 1 clinical trial

Halozyme Therapeutics, Inc. today announced that the first healthy subject has been dosed in a Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of a subcutaneous formulation of rivipansel, a compound discovered by GlycoMimetics, Inc. and being developed by Pfizer Inc., using Halozyme's ENHANZE formulation.

30 Oct 2015

Scientists one step closer to developing new treatment for inflammatory bowel disease

For patients with inflammatory bowel disease, the possibility of taking a single pill to bring long-lasting relief might seem too good to be true. Scientists at the Lewis Katz School of Medicine at Temple University are on the brink of making that happen, thanks to a recent proof-of-concept study, in which the severity of a form of inflammatory bowel disease in mice was dramatically reduced with one oral dose of a protein isolated from a bacterial biofilm.

30 Oct 2015

Transition Therapeutics Ireland signs agreement for investigator-led TT701 Phase 2 clinical study

Transition Therapeutics Inc. announced today that Transition Therapeutics Ireland Limited has entered into an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women's Hospital.

30 Oct 2015

Ultragenyx, Arcturus sign agreement to develop mRNA therapeutics to certain rare diseases

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Arcturus Therapeutics, Inc., a leading RNA medicines company, today announced that they have entered into a research collaboration and license agreement to discover and develop messenger RNA (mRNA) therapeutics to certain rare disease targets using Arcturus' UNA Oligomer chemistry and LUNAR nanoparticle delivery platform.

29 Oct 2015

Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman

For about the last 25 years, the cardiology group here have been developing a platform technology for both the diagnosis and treatment of atherosclerosis.

From Beckman Coulter Life Sciences - Particle Counting and Characterization 28 Oct 2015

Drug that relieves opioid-induced constipation may help some cancer patients live longer

Patients with advanced cancers who took a drug designed to relieve constipation caused by pain killers lived longer and had fewer reports of tumor progression than cancer patients who did not receive the drug, according to results presented October 27 at the 2015 meeting of the American Society of Anesthesiologists in San Diego. This is the first study in humans to associate opioid blockade with improved survival.

28 Oct 2015

Virginia Tech researchers study how specific cytokine influences gene expression patterns in T helper cells

Environment can make all the difference in behavior - even at the cellular level. Scientists at the Virginia Tech Carilion Research Institute have discovered even a small shift in environmental factors can change how a cell in the immune system matures.

28 Oct 2015

New drug combination may be effective against malignant melanoma

A team of Massachusetts General Hospital investigators has discovered a new combination of drugs that may be effective against one of the deadliest cancers, malignant melanoma. The combination - pairing a drug targeted against mutations in the BRAF gene with a second drug that targets another important signaling pathway - was discovered through one of the largest screens of cancer drug combinations conducted to date.

27 Oct 2015

Ipsen, EpiVax partner to create next generation botulinum neurotoxin and TSI therapeutics

Ipsen and the US company EpiVax, Inc. today announced that they have completed a collaborative project that provides a novel approach for creating next generation botulinum neurotoxin (BoNT) and Targeted Secretion Inhibitor (TSI) therapeutics.

27 Oct 2015

Mast Therapeutics begins vepoloxamer Phase 2 study in patients with chronic heart failure

Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, announced that it has initiated its Phase 2 study of vepoloxamer for the treatment of patients with chronic heart failure.

26 Oct 2015

New approaches to treating lung cancer patients in New Mexico

This year, more than 158,000 Americans are expected to die from lung cancer. That's a staggering number: it's more than all the deaths expected from breast, prostate, colon, rectum, bladder and skin cancers combined.

26 Oct 2015

Amgen's IMLYGIC receives positive opinion from CHMP for treatment of melanoma

Amgen today announced that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has adopted a positive opinion recommending that IMLYGIC (talimogene laherparepvec) be granted approval for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.

23 Oct 2015

Study shows promise for developing targeted treatments for multiple sclerosis

Modern scientific understanding has considered multiple sclerosis (MS) to be a disease controlled by the T cell, a type of white blood cell. Research has shown that in MS, T cells inappropriately attack myelin, the protective layer of fat covering nerves in the central nervous system, exposing them to damage.

23 Oct 2015

Juneau Biosciences presents new genetic discoveries in endometriosis at annual ASRM meeting

This week, Juneau Biosciences, LLC presented new discoveries concerning the genetics of endometriosis at the annual American Society of Reproductive Medicine (ASRM) meeting in Baltimore, MD.

23 Oct 2015

Researchers use cutting edge genomic methods to explain protective effects of malaria vaccine candidate

An international team led by researchers from the Broad Institute of MIT and Harvard, the Harvard T.H. Chan School of Public Health, and Fred Hutchinson Cancer Research Center have used cutting edge genomic methods to uncover key biological insights that help explain the protective effects of the world's most advanced malaria vaccine candidate, RTS,S/AS01 (RTS,S).

22 Oct 2015

Therapeutics News and Research

Stem cell transplantation may offer viable treatment for Alzheimer's disease patients

Q BioMed signs definitive license agreement with Mannin Research

Specialized type of immunotherapy can boost survival from pancreatic cancer

New online tool may allow researchers explore formation of hair follicles

Isis Pharmaceuticals begins ISIS-FXI Rx Phase 2 study in patients with ESRD on hemodialysis

Halozyme Therapeutics announces initiation of rivipansel Phase 1 clinical trial

Scientists one step closer to developing new treatment for inflammatory bowel disease

Transition Therapeutics Ireland signs agreement for investigator-led TT701 Phase 2 clinical study

Ultragenyx, Arcturus sign agreement to develop mRNA therapeutics to certain rare diseases

Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman

Drug that relieves opioid-induced constipation may help some cancer patients live longer

Virginia Tech researchers study how specific cytokine influences gene expression patterns in T helper cells

New drug combination may be effective against malignant melanoma

Ipsen, EpiVax partner to create next generation botulinum neurotoxin and TSI therapeutics

Mast Therapeutics begins vepoloxamer Phase 2 study in patients with chronic heart failure

New approaches to treating lung cancer patients in New Mexico

Amgen's IMLYGIC receives positive opinion from CHMP for treatment of melanoma

Study shows promise for developing targeted treatments for multiple sclerosis

Juneau Biosciences presents new genetic discoveries in endometriosis at annual ASRM meeting

Researchers use cutting edge genomic methods to explain protective effects of malaria vaccine candidate

Industry Focus eBook - Biotechnology (4th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News